Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 1/2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 174Neoplasm Metastasis 139Neoplasms 133Leukemia, Myeloid, Acute 127Colorectal Neoplasms 126Breast Neoplasms 113Melanoma 88Ovarian Neoplasms 87Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 79Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 71Lung Neoplasms 70Lymphoma, Non-Hodgkin 62Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 56Stomach Neoplasms 52Glioma 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 47Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Advanced Solid Tumors 39Lymphoma, Follicular 38

Interventions

sodium thiosulfate 1Platinum 1Magnetic Resonance Spectroscopy 1Hearing 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hearing Loss × 90 days × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡